圣达生物董事会审议外汇业务议案，2025年业绩预增

Core Viewpoint - The company, Shengda Bio (603079), is expected to see a significant increase in net profit for 2025, supported by industry conditions, despite recent fluctuations in funding [1][3][4] Recent Events - On February 10, 2026, Shengda Bio held its fifth second board meeting to review a proposal regarding the use of foreign exchange derivatives, which pertains to the company's foreign exchange risk management and may impact future financial strategies [2] Performance and Operating Conditions - On January 23, 2026, the company announced a projected net profit for 2025 ranging from 50 million to 65 million yuan, representing a year-on-year growth of 69.93% to 120.90%. Final financial data will be confirmed in the upcoming annual report [3] Funding Conditions - The company has experienced significant fluctuations in its funding situation recently, but its long-term fundamentals are supported by favorable industry conditions. Further developments will be based on official announcements from the company [4]